AUROBINDO PHARMA LTD
Add to watch list to get report alerts
BSE Code:
524804
NSE Code:
AUROPHARMA
Business Profile
Business Profile
Aurobindo Pharma (AUROBINDOP) was founded in 1986 by P.V.Ramaprasad Reddy, K.Nityananda Reddy and a small, highly committed set of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.
Aurobindo Pharma is a fast-track integrated pharmaceutical company headquartered in Hyderabad, India, producing and marketing active pharmaceutical ingredients (bulk actives), intermediates and specialty generic formulations.
AUROBINDOP ranks among the top five pharma companies in India and is a multi product, multi technology, transnational company. The company`s products serve consumers in India and over 100 other countries including the markets of United States and Europe.
Aurobindo Pharma is an R&D driven chemistry business house with a very broad product portfolio. The company has a presence in fast growing life style disease drugs, anti infective drugs, and key specialty therapeutics.
Aurobindo Pharma is a known leader in the semi synthetic penicillin and cephalosporin. After creating a name for it in producing APIs and intermediates, the company sees major growth in its specialty generic formulations business. In December 29, 2006, Agile Pharma B.V., the ultimate subsidiary of AUROBINDOP acquired 100% stake in the share capital of Pharmacin International B.V., The Netherlands
AUROBINDOP sees its potential both in regulated and other global markets. In regulated markets, Aurobindo Pharma visualises profits aided by the thrust in building intellectual property. In the large growth segments of other global markets, it will succeed by virtue of its cost-efficient production. The company is based at Hyderabad, India.
Financials
The company reported a growth in standalone net profit for the quarter ended March 2009. During the quarter, the profit of the company rose 18.80% to Rs 903.80 million from Rs 760.80 million in the same quarter last year. Net sales for the quarter rose 21.76% to Rs 7699.80 million, while total income for the quarter rose 20.22% to Rs 7709.6 million, when compared with the prior year period. It posted earnings of Rs 16.81 a share during the quarter, registering 18.80% growth over previous year period.
Recent Developments
29-MAY-09
The company announced that its US joint venture Cephazone Pharma LLC received approval for its original Abbreviated New Animal Drug Application (ANADA) for ceftiofur sodium sterile powder from the US Food and Drug Administration Center for veterinary medicines.
11-MAY-09
The company`s wholly owned subsidiary Aurobindo Pharma Australia Pty has received another approval from the therapeutic goods administration (TGA), Government of Australia for the registration of Simvastatin tablets 5,10,20,40 and 80 mg.
08-APR-09
The company has received first product approval from Swissmedic, Government of Switzerland for license Finasteride APL Tablets 5mg.
31-MAR-09
The company received tentative approval for Emtricitabine/Tenofovir Disoproxil Fumarate Tablets, 200mg/300mg from the US Food & Drug Administration (USFDA).
28-MAR-09
The company received final approval from the US Food and Drug Administration (USFDA) to market Topiramate Tablet in the strength of 25 mg, 50 mg, 100 mg and 200 mg.
20-MAR-09
The drug maker`s Australian arm, Aurobindo Pharma Australia obtained its second approval from Therapeutic Goods Administration, Australia, Government of Australia for the registration of Sertraline 50 mg and 100 mg blister pack tablets containing Sertraline 50 mg and 100 mg.
19-MAR-09
The company has received registrations from the Medicines Control Council (MCC) to manufacture and market 3 drugs in South Africa.
12-MAR-09
The company has received a tentative approval for Lopinavir / Ritonavir Tablets, 100/25 mg and 200/50 mg from US Food & Drug Administration (USFDA).
03-MAR-09
The company entered in to a series of agreements with Pfizer, a global leader in Pharmaceuticals
02-MAR-09
The company`s Australian subsidiary received its first approval from Therapeutic Goods Administration (TGA), government of Australia for the registration of Auro-Lisinopril 5, Auro-Lisinopril 10 and Auro-Lisinopril 20 tablets containing Lisinopril (as dihydrate) 5mg, 10 mg and 20 mg.
24-FEB-09
The company received a tentative approval for Tenofovir Disoproxil Fumarate Tablet, 300 mg from US Food & Drug Administration (USFDA).
20-FEB-09
The company received tentative approval for Tenofovir Disoproxil Fumarate Tablet, 300 mg from US Food & Drug Administration (USFDA).
30-JAN-09
The company received final approval from the US Food and Drug Administration to market Lamotrigine tablet, in the strengths of 25 mg, 100 mg, 150 mg and 200 mg.
06-JAN-09
The company has announced that it had received the approval for its abbreviated new drug submission, Gabapentine Capsules from Health Canada.